ASH Letter to FDA re Considerations for the Development of CAR T Products

American Society of Hematology. (2022).
ASH Letter to FDA re Considerations for the Development of CAR T Products.
Retrieved from https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-to-fda-re-considerations-for-the-development-of-car-t-products.

American Society of Hematology.
"ASH Letter to FDA re Considerations for the Development of CAR T Products." Hematology.org.
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-to-fda-re-considerations-for-the-development-of-car-t-products
(label-accessed May 30, 2025).

"American Society of Hematology."
ASH Letter to FDA re Considerations for the Development of CAR T Products, 30 May. 2025 ,
https://www.hematology.org/advocacy/testimony-and-correspondence/ash-letter-to-fda-re-considerations-for-the-development-of-car-t-products.

Citation Manager Formats

• BibLaTeX
• Bookends
• EasyBib
• EndNote
• Mendeley
• Papers
• RIS
• Ref Manager
• RefWorks
• Zotero